Dossier assessment
Tisotumab vedotin (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Tisotumab vedotin (cervical cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Tisotumab vedotin (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult patients with recurrent or metastatic cervical cancer
Result of dossier assessment:
- Patients with disease progression during or after platinum-based first-line chemotherapy who have not been pretreated with a PD-(L)1 antibody and for whom further antineoplastic therapy is an option: added benefit not proven
- Patients with disease progression during or after platinum-free first-line chemotherapy without a PD-(L)1 antibody or first-line combination therapy consisting of chemotherapy and a PD-(L)1 antibody or sequential therapy with platinum-containing chemotherapy and a PD-(L)1 antibody and for whom further antineoplastic therapy is an option: added benefit not proven
- Patients with disease progression during or after prior systemic therapy for whom further antineoplastic therapy is not an option: added benefit not proven
Project details
- Project no.
- A25-112
- Commission
- Commission awarded on 29.08.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-112_en